Sourcing medicines for the UK market

AI Summary

This guidance document from the UK Medicines and Healthcare products Regulatory Agency (MHRA) establishes the protocols for sourcing and importing medicines under the Human Medicines Regulations 2012. While no specific inspection dates or violations are cited in this general guidance, it identifies essential compliance standards to prevent regulatory breaches regarding wholesale activities. The regulatory framework distinguishes between Great Britain and Northern Ireland, specifying that medicines certified in the European Economic Area (EEA) generally do not require re-testing upon entry into Great Britain, provided specific oversight is maintained. A critical requirement for compliance is the appointment of a Responsible Person for Import (RPi) for Great Britain-based wholesalers, though this oversight is not required for Northern Ireland entities. The document outlines four distinct licensing categories that wholesale dealer authorization holders must obtain depending on the product’s authorization status and intended market, such as parallel imports or export-only goods. Required actions for companies include verifying that source countries appear on the UK’s approved list, ensuring their license specifically authorizes functions like Article 51 certification handling, and maintaining proper notification procedures for unlicensed 'special' medicines. Adherence to these categories ensures that the pharmaceutical supply chain remains secure while facilitating the movement of medicinal products across borders.